Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen and M.D. Anderson Cancer Center Sign Ovarian Cancer Biomarker Collaboration

NEW YORK, Feb. 15 (GenomeWeb News) - Ciphergen Diagnostics, a division of Ciphergen Biosystems, has signed a research and license agreement with the University of Texas M.D. Anderson Cancer Center to discover ovarian cancer biomarkers, the company said today.

 

Under the agreement, M.D. Anderson will provide Ciphergen with clinical samples which Ciphergen will analyze using its ProteinChip mass spectrometry technology and bioinformatics tools. The aim is to validate ovarian cancer biomarkers found earlier, to discover markers to distinguish ovarian cancer from other gynecological disorders, and to predict treatment response.

 

Ciphergen can exclusively license discoveries from the collaboration, and other cancer projects may be added later to the agreement.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.